Anti-Malarial Research Continues with Grant
BOSTON - Paratek Pharmaceuticals has received a Phase I Small Business Innovative Research grant from the National Institute of Allergy and Infectious Diseases to research novel tetracycline derivatives for activity against Plasmodium falciparum.
"Doxycycline, a form of tetracycline, has been used against malaria for years, both to treat and prevent malaria," says Ken Takana, PHD, Paratek's vice president of research and development. "We want to add new tetracyclines to the public health arsenal that offer improvements over doxycycline and other current therapies."
The company has a variety of research interests, including antimalarial drugs. Officials are examining the non-antibiotic properties of tetracyclines as antifungals, anti-inflammatories, neuroprotectives and other applications.
It is estimated that malaria infects 300 million globally, killing more than 1 million annually.
For more information, visit: www.paratekpharm.com.
Endoscopes and Lumened Instruments: New Studies Highlight Persistent Contamination Risks
May 7th 2025Two new studies reveal troubling contamination in both new endoscopes and cleaned lumened surgical instruments, challenging the reliability of current reprocessing practices and manufacturer guidelines.
Happy Hand Hygiene Day! Rethinking Glove Use for Safer, Cleaner, and More Ethical Health Care
May 5th 2025Despite their protective role, gloves are often misused in health care settings—undermining hand hygiene, risking patient safety, and worsening environmental impact. Alexandra Peters, PhD, points out that this misuse deserves urgent attention, especially today, World Hand Hygiene Day.
